; (3) assist State and local law enforcement agencies in testing seized drugs when State and local forensic laboratories request additional assistance; and (4) provide early warning information and advice to Federal, State, and local law enforcement agencies and public health authorities of potential significant changes in the supply of fentanyl, its analogues, and other synthetic opioids. (d) Authorization of appropriations To carry out this section, there is authorized to be appropriated $15,000,000 for each of fiscal years 2018 through 2022. 3. Enhanced fentanyl surveillance (a) In general The Director of the Centers for Disease Control and Prevention shall enhance its drug surveillance program by— (1) expanding its surveillance program to include all 50 States and the territories of the United States; (2) increasing and accelerating the collection of data on fentanyl, its analogues, and other synthetic opioids, including related overdose data from medical examiners and drug treatment admissions; and (3) utilizing available and emerging information on fentanyl, its analogues, and other synthetic opioids, including— (A) the National Drug Early Warning System; (B) State and local public health authorities; and (C) Federal, State, and local public health laboratories. (b) Authorization of appropriations To carry out this section, there is authorized to be appropriated $10,000,000 for each of fiscal years 2018 through 2022. 4. Pilot program for point-of-use testing of illicit drugs for dangerous contaminants (a) In general The Secretary of Health and Human Services, acting through the Assistant Secretary for Mental Health and Substance Use, in coordination with the Director of the Centers for Disease Control and Prevention, shall— (1) establish a pilot program through which 5 State or local agencies conduct, in 5 States, point-of-use testing of illicit drugs for dangerous contaminants; (2) establish metrics to evaluate the success of the pilot program in reducing drug overdose rates